MedDataX Logo

Docetaxol Plus Cisplatin Versus 5-Fu Plus Cisplatin as 1st-line Chemotherapy in Advanced ESCC Patients

NCT03002064 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 358

Last updated 2016-12-26

No results posted yet for this study

Summary

This is a phase III clinical trial to compare the efficacy of docetaxel plus cisplatin versus 5-Fu plus cisplatin in the first line chemotherapy for advanced or metastatic esophageal squamous carcinoma patients.

Conditions

  • Esophagus Cancer
  • Chemotherapy Effects

Interventions

DRUG

Docetaxel

60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.

DRUG

Fluorouracil

5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles

DRUG

Cisplatin

Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Rui-Hua Xu, MD, PhD · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2019-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03002064 on ClinicalTrials.gov